Mustang Bio (NASDAQ:MBIO) Issues Earnings Results, Beats Estimates By $0.09 EPS

Mustang Bio (NASDAQ:MBIO) issued its earnings results on Friday. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09, Zacks reports.

Mustang Bio Price Performance

NASDAQ:MBIO remained flat at $0.26 during trading hours on Monday. 1,515,232 shares of the company were exchanged, compared to its average volume of 9,262,874. The company has a market capitalization of $9.57 million, a price-to-earnings ratio of -0.16 and a beta of 1.92. The firm’s 50-day moving average price is $0.25 and its 200-day moving average price is $0.31. Mustang Bio has a one year low of $0.13 and a one year high of $1.73.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.